Ignite Creation Date:
2025-12-25 @ 12:14 AM
Ignite Modification Date:
2025-12-25 @ 10:15 PM
Study NCT ID:
NCT05172258
Status:
ACTIVE_NOT_RECRUITING
Last Update Posted:
2025-09-16
First Post:
2021-12-28
Is NOT Gene Therapy:
False
Has Adverse Events:
False
Brief Title:
Testing the Addition of an Anti-cancer Drug, Ipatasertib, to the Usual Immunotherapy Treatment (Pembrolizumab) in Patients With Recurrent or Metastatic Squamous Cell Cancer of the Head and Neck
Sponsor:
National Cancer Institute (NCI)
Organization:
Key Dates - Follows AllAPIJSON File Order
Start Date:
2022-07-26
Start Date Type:
ACTUAL
Primary Completion Date:
2027-06-30
Primary Completion Date Type:
ESTIMATED
Completion Date:
2027-06-30
Completion Date Type:
ESTIMATED
First Submit Date:
2021-12-28
First Submit QC Date:
None
Study First Post Date:
2021-12-29
Study First Post Date Type:
ACTUAL
Results First Submit Date:
None
Results First Submit QC Date:
None
Results First Post Date:
None
Results First Post Date Type:
None
Results First Post QC Date:
None
Results First Post QC Date Type:
None
Disp First Submit Date:
None
Disp First Submit QC Date:
None
Disp First Post Date:
None
Disp First Post Date Type:
None
Last Update Submit Date:
2025-09-13
Last Update Post Date:
2025-09-16
Last Update Post Date Type:
ESTIMATED